Nan-Ya Ken-ichiro, Kajihara Masatomo, Kojima Natsuki, Degawa Masakuni
Drug Discovery Research Laboratories, Kyowa Hakko Kirin Co., Ltd, 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan; Department of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
J Appl Toxicol. 2015 Feb;35(2):124-32. doi: 10.1002/jat.2999. Epub 2014 Apr 16.
We explored biomarkers suitable for monitoring sub-chronic kidney injury using the three rat models of cisplatin (CDDP)-induced kidney injury, which were designed to extend the current knowledge beyond the sub-acute exposure period. In the pilot study, a single intravenous administration of 1.5 mg kg(-1) CDDP to rats was confirmed to result in no histopathological changes. Subsequently, CDDP was intravenously administered to rats at a dose of 1.5 mg kg(-1) for 4 days at 24-h intervals (Experimental model 1) and for up to 10 weeks at weekly intervals (Experimental models 2 and 3), and the changes in blood and urine components, such as recently recommended urinary biomarkers (Kim-1, clusterin and so on) and traditional blood biomarkers (blood urea nitrogen and serum creatinine), were examined together with the histopathological changes in renal tissues during the development of the kidney injury in each model. In these experimental models, a significant increase in urinary Kim-1 was observed prior to the histopathological changes in renal tissues, and these changes were retained after the adverse histopathological changes. Significant changes in all of the other urinary biomarkers examined occurred along with the histopathological changes. In addition, the increase in urinary Kim-1 after weekly treatment with CDDP for 4 weeks was reduced in a time-dependent manner after cessation of the drug. The present findings indicate that urinary Kim-1 is the most useful biomarker for CDDP-induced rat sub-chronic kidney injury among the biomarkers examined.
我们使用三种顺铂(CDDP)诱导的肾损伤大鼠模型,探索了适用于监测亚慢性肾损伤的生物标志物,这些模型旨在扩展当前对亚急性暴露期以外情况的认识。在预实验中,确认对大鼠单次静脉注射1.5 mg kg⁻¹ CDDP不会导致组织病理学变化。随后,以1.5 mg kg⁻¹ 的剂量对大鼠静脉注射CDDP,实验模型1为每隔24小时注射1次,共注射4天;实验模型2和3为每周注射1次,共注射长达10周。在每个模型肾损伤发展过程中,检测血液和尿液成分的变化,如最近推荐的尿液生物标志物(Kim-1、簇集素等)和传统血液生物标志物(血尿素氮和血清肌酐),同时检测肾组织的组织病理学变化。在这些实验模型中,在肾组织出现组织病理学变化之前,尿液Kim-1就显著增加,并且在出现不良组织病理学变化后这些变化仍然存在。所检测的所有其他尿液生物标志物的显著变化都与组织病理学变化同时出现。此外,在停止用药后,每周用CDDP治疗4周后尿液Kim-1的增加呈时间依赖性降低。目前的研究结果表明,在所检测的生物标志物中,尿液Kim-1是CDDP诱导的大鼠亚慢性肾损伤最有用的生物标志物。